"Chevy Chase Clinical Research is the largest research center of its kind in the region with approximately 90,000 patients in its database. Established in 1996 as part of Affiliated Research Centers, it is now an independent research site. Under the direction of Medical Director Dr. Aamir Ali, more than 300 studies have been conducted in all areas of Gastroenterology and some areas of Internal Medicine."

During the past decade, Chevy Chase Clinical Research conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 26 clinical trials were completed, i.e. on average, 74.3% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 18 clinical trials were completed. i.e. 138.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chevy Chase Clinical Research" #1 sponsor was "Celgene" with 6 trials, followed by "Shire" with 6 trials sponsored, "Exact Sciences Corporation" with 5 trials sponsored, "Takeda" with 4 trials sponsored and "Allergan" with 4 trials sponsored. Other sponsors include 41 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chevy Chase Clinical Research" #1 collaborator was "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Athersys, Inc" with 1 trials as a collaborator, "Elan Pharmaceuticals" with 1 trials as a collaborator and "Ironwood Pharmaceuticals, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Chevy Chase Clinical Research" are "Ulcerative Colitis" (16 trials), "Crohn's Disease" (14 trials), "Colitis, Ulcerative" (8 trials), "Colorectal Cancer" (6 trials) and "Gastroparesis" (4 trials). Many other conditions were trialed in "Chevy Chase Clinical Research" in a lesser frequency.

Most popular intervention types in "Chevy Chase Clinical Research" are "Drug" (58 trials), "Biological" (7 trials), "Other" (5 trials), "Device" (2 trials) and "Diagnostic Test" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "AQUAVAN® (fospropofol disodium) Injection" (3 trials), "Adalimumab" (3 trials), "Etrasimod" (3 trials) and "RPC1063" (3 trials). Other intervention names were less common.

The vast majority of trials in "Chevy Chase Clinical Research" are 68 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Chevy Chase Clinical Research". undefined are not yet recruiting, 5 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 49 completed trials in Chevy Chase Clinical Research, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Chevy Chase Clinical Research, 1 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 38 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".